IMUGENE LIMITED — Board/Management Information 2013

Feb 10, 2013

==> picture [140 x 46] intentionally omitted <==

Imugene Announces Board and Management Changes

Melbourne, 11 February 2013 : Imugene (ASX.IMU) has announced changes to its Board of Directors today with the resignation of Mr Fabio Pannuti, who will stand down as Executive Chairman and from the Company’s Board of Directors, effective immediately.

Non-Executive Director Mr Steve Harris will assume the role of Non-Executive Chairman and Dr. Nicholas Ede has been appointed Executive Director. Mr Paul Hopper continues in his role as non-Executive Director.

Mr Harris said, “We thank Mr Pannuti for his contribution in progressing the company’s drug delivery assets, which are now well placed for significant advancement”.

Dr. Ede has a record of successfully evolving research concepts to commercial products and processes. He has over 25 years’ experience in drug discovery and international business development gained at Chiron, EqiTX, Mimotopes and Adistem. He holds a PhD from Monash University and Grad. Cert. in Innovation from Melbourne Business School, and has published over 50 scientific papers and patents.

Mr Harris commented, “Dr. Ede’s appointment has come at a pivotal time in the strategic development of Imugene. He adds further potency to the team with his extensive knowledge and his impressive track record of product development and commercialisation in the biotechnology sector.

"I am delighted to be joining the team at Imugene. The Company is at an exciting stage and I have been very impressed both by the caliber of the people and the quality of the science and business plan. I look forward to working with the Board and Management Team to create real and sustainable shareholder value." said Dr. Ede.

Imugene is focused on the commercialisation of a class of drugs known as generics plus - taking known molecules and delivering them better. Rather than being a drug delivery company focused on any one technology, the business focuses on unmet needs using established molecules and working with a range of technologies. The first target is an improved version of Vitamin D, with greater potency, that utilises its drug delivery technology Linguet™, a proprietary drug delivery technology that can improve the efficacy and safety of a range of prescription and over the counter medicines.

Change of Registered Office

The registered office of the Company has changed effective today to:

Suite 1, 1233 High Street, Armadale Victoria 3143 Phone: +61 (0)3 9824 5254 Fax: +61 (0)3 9822 7735

For more information please visit www.imugene.com .

Ends

Suite 1, 1233 High Street Armadale, Victoria Australia 3143

Imugene Limited ABN 99 009 179 551 www.imugene.com.au

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735